Next-Generation CAR T-Cells to Cure Cancer Gene Edited Off-the-shelf Immunotherapies: A Future-defining Shift in Simplicity, Availability, and Cost-effectiveness LEARN MORE WATCH THE VIDEO TALEN® enables gene editing at industrial scale Gene editing will completely reshape molecular medicine within five years. Our flagship TALEN® technology provides us with the ability to rethink how we treat diseases altogether. Cells can be engineered with optimized features for cancer therapies, drug discovery, gene function studies, industrial biotechnology and more. It is the next transformative step in medicine. LEARN MORE "Off-the-shelf" immunotherapies that can work for the largest number of patients Cellectis gene-edits “Chimeric Antigen Receptor” (CAR) T-cells from healthy donors into “off-the-shelf” immunotherapy product candidates that are designed to work for the largest number of patients. It’s the difference between being an off-the-shelf product and a service in which each treatment has to be custom-made. This same technology, developed by Cellectis, could help in designing therapies for many other diseases. LEARN MORE Strong intellectual property, global strategic partnerships. 18 years of innovation. 175 patent families. 163 granted patents and 737 applications. Global strategic partnerships with Allogene, Servier, and leading Universities all over the world. LEARN MORE Editing Life PRESS CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board Published on: September 19, 2018, 16:30 E.S.T. Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP Published on: September 18, 2018, 16:30 E.S.T. Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer Published on: August 02, 2018, 16:30 E.S.T. Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 Published on: August 01, 2018, 16:30 E.S.T. Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports Published on: June 12, 2018, 16:30 E.S.T. FDA Grants Cellectis IND Approval for UCART22 in B-ALL Published on: June 04, 2018, 16:30 E.S.T. CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board September 19, 2018 – New York – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced that Stephan A. Grupp, MD, Ph.D., a leading pediatric oncologist at Children's Hospital of Philadelphia and Chief of the Section of Cellular Therapy and Transplant at the Children's Hospital of Philadelphia (CHOP) joined the Company’s Clinical Advisory Board (CAB). READ MORE ALL PRESS RELEASES LEGAL NOTICE CAREERS GLOSSARY MEDIA LIBRARY CONTACT Subsidiary: Calyxt Inc.